F. Cañas and H. S. Möller, Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review, Expert Opin Drug Saf, vol.9, pp.683-97, 2010.

W. W. Fleischhacker, Second-generation antipsychotic long-acting injections: systematic review, Br J Psychiatry, vol.52, pp.29-36, 2009.

M. K. Rainer, Risperidone long-acting injection: a review of its long term safety and efficacy, Neuropsychiatr Dis Treat, vol.4, pp.919-946, 2008.

N. C. Andreasen, W. Carpenter, J. M. Kane, R. A. Lasser, S. R. Marder et al., Remission in schizophrenia: proposed criteria and rationale for consensus, Am J Psychiatry, vol.162, pp.441-450, 2005.

R. A. Lasser, C. A. Bossie, G. M. Gharabawi, and J. M. Kane, Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection, Schizophrenia Res, vol.77, pp.215-242, 2005.

W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours et al., Direct transition to long-acting risperidone -analysis of long-term efficacy, J Psychopharmacol, vol.19, pp.15-21, 2005.

P. M. Llorca, E. Sacchetti, K. Lloyd, W. Kissling, and R. Medori, Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months, Intl J Clin Pharmacol Ther, vol.46, pp.14-22, 2008.

H. Möller, P. Llorca, E. Sacchetti, S. D. Martin, R. Medori et al., Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies, Intl Clin Psychopharmacol, vol.20, pp.121-151, 2005.

S. Z. Levine, J. Rabinowitz, H. Ascher-svanum, D. E. Faries, and A. H. Lawson, Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study, Schizophrenia Res, vol.133, pp.42-48, 2011.

S. Leucht, Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application, J Clin Psychiatry, vol.75, pp.8-14, 2014.

F. Rosa, A. Schreiner, P. Thomas, and T. Sherif, Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable, Clin Drug Invest, vol.32, pp.267-79, 2012.

K. Lloyd, M. A. Latif, S. Simpson, and K. L. Shrestha, Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome, Human Psychopharmacol Clin Expl, vol.25, pp.243-52, 2010.

F. Rouillon, L. Eriksson, B. Burba, J. Raboch, G. Kaprinis et al., Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE), Acta Neuropsychiatrica, vol.25, pp.297-306, 2013.

P. M. Llorca, P. Bouhours, and V. Moreau-mallet, Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone, Encephale, vol.34, pp.170-178, 2008.

M. Lambert, D. Marinis, T. Pfeil, J. Naber, D. Schreiner et al., Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment, Eur Psychiatry, vol.25, pp.220-229, 2010.

C. Bonaïti-pellié, P. Arveux, B. De-villemeur, A. Dantchev, N. Elbaz et al., Traitement de l'information en matière de recherche dans le domaine de la santé, Med Sci (Paris), vol.25, pp.93-101, 2009.

, des études, de l'évaluation et des statistiques, vol.88, p.1, 2005.

A. Martinez-aran, E. Vieta, C. Torrent, J. Sanchez-moreno, J. M. Goikolea et al., Functional outcome in bipolar disorder: the role of clinical and cognitive factors, Bipolar Disorders, vol.9, pp.103-116, 2007.

Y. Braw, R. Sitman, M. Cohen, U. Berger, S. Lev-ran et al., Remission of positive symptoms according to the "remission in Schizophrenia Working Group" criteria: A longitudinal study of cognitive functioning, Eur Psychiatry, vol.28, pp.282-289, 2013.

F. Pinna, M. Bosia, R. Cavallaro, and B. Carpiniello, Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances, Schizophrenia Res: Cognition, vol.1, pp.187-92, 2014.

W. C. Chang, T. Chan, E. Chen, C. Hui, G. Wong et al., The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia, Schizophrenia Res, vol.143, pp.107-122, 2013.

H. Heering, M. Janssens, L. Boyette, and N. Van-haren, Remission criteria and functional outcome in schizophrenia patients. A longitudinal study, Schizophrenia Res, vol.153, issue.1, pp.166-173, 2014.

F. Pinna, L. Deriu, T. Lepori, R. Maccioni, P. Milia et al., Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders, Psychiatry Res, vol.210, pp.739-783, 2013.

P. Rocca, C. Montemagni, F. Castagna, M. Giugiario, M. Scalese et al., Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia, Progress NeuroPsychopharmacol Biological Psychiatry, vol.33, pp.373-382, 2009.